Letrozole: a new treatment for delayed puberty in boys? by Dattani, MT
A novel treatment for delayed puberty? 
 
Puberty is a complex physiological process that culminates in the attainment of sexual maturity and the potential 
for reproduction and fertility. The process is regulated by the hypothalamo-pituitary-gonadal (HPG) axis, which 
is initially activated prenatally and during infancy, followed by a period of latency until its reactivation in later 
childhood. The age of pubertal initiation is highly variable (8-12 years in females, 9-14 years in males). The 
exact stimulus that leads to a reactivation of the HPG axis at the time of puberty is largely unknown; however 
recent data have suggested a role for factors such as Kisspeptin and Makorin ring finger protein 3 (MKRN3) in 
the initiation of the pulsatile secretion of gonadotrophin-releasing hormone (GnRH) with consequent 
gonadotropin pulsatility leading to gonadal sex steroid secretion (1). Puberty may be pathologically early, but is 
more frequently delayed, particularly in males.  
 
Pubertal delay may be due to a number of causes, and these include a failure to activate and maintain 
gonadotrophin secretion following the pulsatile secretion of GnRH (hypogonadotrophic hypogonadism) (2). This 
may be congenital, when it can be caused by mutations in one or more of a number of genes regulating GnRH 
and gonadotrophin secretion, or acquired due to the presence of tumours, inflammation (eg Langerhans Cell 
Histiocytosis) or infiltration (eg Thalassaemia) (3). However, the most frequent cause of delayed puberty 
presenting to paediatric and adolescent endocrinologists is Constitutional delay of growth and puberty (CDGP) 
(2). This is a variant of normal puberty that appears to be commoner in males, and is characterised by delayed 
maturation of the HPG axis with a consequent lack of gonadal sex steroid secretion and sexual development. 
Short stature with reduced growth hormone (GH) secretion and a low concentration of insulin-like growth factor 
1 (IGF-1) may be associated with a reduced growth velocity, as GH secretion is highly dependent on sex steroid 
production during adolescence. The condition is benign and self-limiting, but may be associated with 
considerable psychological distress and poor self-esteem which may impact on both academic attainment as well 
sporting prowess. The cause is largely unknown, although 50 to 75% of patients with CDGP have a family 
history of delayed puberty (2). Recently, a molecular basis has been identified in some cases, with mutations in 
IGSF10 being identified in some familial cases (4). The diagnosis is largely one of exclusion, and the main 
differential is hypogonadotrophic hypogonadism; distinction between the two conditions may be difficult and 
largely retrospective (2, 5, 6). Both conditions may be treated by the administration of low doses of sex steroids 
(oral/intramuscular/topical testosterone or oral/topical oestrogen) (2,3,7,8). Although this is a safe and effective 
therapy that is associated with an increase in IGF-1 concentrations with a concomitant increase in growth 
velocity, improvement in sexual maturation, and psychological wellbeing, it could nevertheless potentially be 
associated in males with reduced testicular volumes as well as bone maturation with a reduction in final height, 
although long-term data are lacking. Other therapeutic modalities include the use of gonadotrophins, which have 
been used in a small number of cases where the diagnosis of hypogonadotrophic hypogonadism is highly likely 
or confirmed (3). It should not be used in patients with CDGP, as although this may be associated with gonadal 
development, the treatment is nevertheless cumbersome and expensive.  
 
In this issue, Raivio et al. report the findings of a multi-centre, randomised, controlled, open-label trial 
comparing the use of a third generation aromatase inhibitor, peroral Letrozole, with monthly low-dose 
intramuscular testosterone injections given over a 6 month period, with a further 6 month follow up period (9). 
Aromatase inhibitors prevent the conversion of androstenedione to estrone and testosterone to estradiol, with the 
desired outcome of delayed epiphyseal maturation and a potential increase in final height. They have previously 
been used in patients with idiopathic short stature and delayed puberty (10-12). In this study, Letrozole treatment 
led to increased concentrations of LH and testosterone, with stable Inhibin B concentrations. On the other hand, 
low-dose testosterone treatment was associated with suppressed gonadotrophin, testosterone and Inhibin B 
concentrations. Testicular growth was faster in the boys treated with Letrozole. Although there was no difference 
in height velocity attained in the two groups, bone age advanced more slowly in the Letrozole-treated boys. 
BMD increased more in the lumbar spine and hips in the testosterone-treated group, but there was no change in 
the BMD adjusted for height (BMAD). The authors conclude that Letrozole therapy may represent a novel and 
effective treatment modality for CDGP boys with early signs of endogenous puberty. 
 
This is an interesting study, which suggests a novel treatment for a relatively common disorder. The treatment 
certainly appears to be effective, and its oral mode of administration is an advantage over parenteral testosterone. 
However, aromatase inhibitors can associated with adverse effects, for example lipid abnormalities and vertebral 
deformities  (13). Although these may not be such an issue with the short-term use of these agents (11), these 
therapeutic agents should nevertheless be used with caution, particularly in patients with CDGP where the 
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